Advertisement

Osteoporosis International

, Volume 16, Issue 1, pp 1–5 | Cite as

Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation

  • Pierre D. DelmasEmail author
  • René Rizzoli
  • Cyrus Cooper
  • Jean-Yves Reginster
Editorial

Although many agents have been used in the treatment of osteoporosis, only in the past 10 years have large, double-blind placebo-controlled trials been published on postmenopausal women with the condition of using incident fractures as the primary endpoint. Several agents have been proven to significantly decrease the risk of vertebral and, in some instances, long bone fractures [1]. Tables 1 and 2show the anti-fracture efficacy of the most commonly used agents for which large fracture trials are available, i.e., the bisphosphonates alendronate and risedronate, the selective estrogen receptor modulator (SERM) raloxifene, the 1–34 fragment of recombinant human parathyroid hormone (teriparatide), and to some extent nasal calcitonin. These agents have consistently shown a substantial reduction of the risk of vertebral fracture ranging from 30–65% according to agent and patient populations. A significant reduction of the risk of nonvertebral fractures has been shown with alendronate and...

Keywords

Bone Mineral Density Vertebral Fracture Teriparatide Risedronate Nonvertebral Fracture 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018–2026CrossRefPubMedGoogle Scholar
  2. 2.
    Recker R, Stakkestad JA, Chesnut CH 3rd, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:890–899CrossRefPubMedGoogle Scholar
  3. 3.
    Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468CrossRefPubMedGoogle Scholar
  4. 4.
    World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, WHO, GenevaGoogle Scholar
  5. 5.
    Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 7:390–406PubMedGoogle Scholar
  6. 6.
    Compston JE, Papapoulos SE, Blanchard F (1998) Report on osteoporosis in the European Community: current status and recommendations for the future. Working Party from European Union Member States. Osteoporos Int 8:531–534CrossRefPubMedGoogle Scholar
  7. 7.
    National Osteoporosis Foundation (1998) Physicians guide to prevention and treatment of osteoporosis, Washington, DCGoogle Scholar
  8. 8.
    National Osteoporosis Foundation (1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int 8 [Suppl 4]:S7–80Google Scholar
  9. 9.
    U.S. Preventive Services Task Force (2002) Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 137:526–528PubMedGoogle Scholar
  10. 10.
    Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK, Shepherd JA, Downs RW Jr (2004) Official positions of the international society for clinical densitometry. J Clin Endocrinol Metab 89:3651–3655CrossRefPubMedGoogle Scholar
  11. 11.
    Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A (2002) Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30:251–258CrossRefPubMedGoogle Scholar
  12. 12.
    Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11 [Suppl 6]:S2–17Google Scholar
  13. 13.
    Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739PubMedGoogle Scholar
  14. 14.
    Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936CrossRefPubMedGoogle Scholar
  15. 15.
    Kanis JA, Gluer CC (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 11:192–202CrossRefPubMedGoogle Scholar
  16. 16.
    Kanis JA, Johnell O, Oden A, Borgstrom F, Johansson H, De Laet C, Jonsson B (2004) Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int (DOI 10.1007/s00198-004-1623-4; this issue)Google Scholar
  17. 17.
    Kanis JA, Borgstrom F, Zethraeus N, Johnell O, Oden A, Jonsson B (2004) Intervention thresholds for osteoporosis in men and women. Bone (in press)Google Scholar
  18. 18.
    Raftery J (2001) NICE: faster access to modern treatments? Analysis of guidance on health technologies. Bmj 323:1300–1303CrossRefPubMedGoogle Scholar
  19. 19.
    Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2004) Cost-effectiveness of raloxifene in the UK—An economic evaluation based on the MORE-study. Osteoporos Int (DOI 10.1007/s00198-004-1688-0; this issue)Google Scholar
  20. 20.
    Delmas PD, Calvo G, Boers M, Abadie E, Avouac B, Kahan A, Kaufman JM, Laslop A, Lekkerkerker JF, Nilsson P, Van Zwieten-Boot B, Kreutz G, Reginster JY (2002) The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporos Int 13:1–5CrossRefPubMedGoogle Scholar
  21. 21.
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541CrossRefPubMedGoogle Scholar
  22. 22.
    Chesnut CH, 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109:267–276CrossRefPubMedGoogle Scholar
  23. 23.
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645CrossRefPubMedGoogle Scholar
  24. 24.
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352CrossRefPubMedGoogle Scholar
  25. 25.
    Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91CrossRefPubMedGoogle Scholar
  26. 26.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefPubMedGoogle Scholar
  27. 27.
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082CrossRefPubMedGoogle Scholar
  28. 28.
    McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan Ge-H, Reda C, Yates AJ, Ravn P (1998) Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 128:253–261PubMedGoogle Scholar
  29. 29.
    Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989–995CrossRefPubMedGoogle Scholar
  30. 30.
    Kanis JA, Oden A, Johnell O, Jonsson B, De Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method of setting intervention threshold. Osteoporos Int 12:417–427CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2004

Authors and Affiliations

  • Pierre D. Delmas
    • 1
    • 5
    Email author
  • René Rizzoli
    • 2
  • Cyrus Cooper
    • 3
  • Jean-Yves Reginster
    • 4
  1. 1.Claude Bernard University of Lyon and INSERM Research Unit 403LyonFrance
  2. 2.University of GenevaGenevaSwitzerland
  3. 3.University of SouthamptonSouthamptonUK
  4. 4.University of LiègeBelgium
  5. 5.Pavillon FHôpital E. HerriotLyon Cedex 03France

Personalised recommendations